<DOC>
	<DOCNO>NCT00004062</DOCNO>
	<brief_summary>RATIONALE : Azacitidine may help thyroid cancer cell regain ability take iodine . This would allow cancer detect treat radioactive iodine . PURPOSE : Phase I trial study effectiveness azacitidine restore thyroid function treat patient persistent metastatic thyroid cancer .</brief_summary>
	<brief_title>Azacitidine Restore Thyroid Function Patients With Persistent Metastatic Thyroid Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine ability azacitidine restore iodine uptake dedifferentiate thyroid cancer , enable detection treatment iodine I 131 patient metastatic follicular papillary thyroid cancer . II . Evaluate different dos schedule azacitidine administration determine optimally effective combination restoration iodine I 131 uptake acceptable toxicity patient population . III . Determine efficacy azacitidine plus iodine I 131 patient population . OUTLINE : This dose escalation study azacitidine . Patients undergo control phase consist oral liothyronine sodium twice daily week 1-4 low iodine diet week 4-7 . At week 6 , patient receive scan dose iodine I 131 follow whole body scan 5 day . Beginning week 7 , patient undergo treatment phase consist oral liothyronine sodium twice daily 3 week , azacitidine subcutaneously daily 10 20 day ( week 7-11 ) low iodine diet week 8-11 . During week 11 , patient undergo additional whole body scan 5 day follow therapeutic dose iodine I 131 . Patients achieve successful therapy receive 5 additional dos azacitidine . Cohorts 4 patient receive escalate dos azacitidine demonstrable radioiodine uptake see maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 8 patient experience dose limit toxicity . Patients follow weekly 8 week . PROJECTED ACCRUAL : A total 38 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Radiologically confirm persistent metastatic follicular papillary thyroid cancer follow total thyroidectomy radioiodine ablation therapy Metastatic disease confirm histologically cytologically elevate thyroglobulin level No radioiodine uptake whole body scan Stable iodine contamination radiologic contrast material within past 10 month allow , absence current contamination demonstrate less 80 microgram iodine 24 hour urine collection PATIENT CHARACTERISTICS : Age : Any age Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : SGOT/SGPT great 2.5 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN Renal : Creatinine great 1.5 time ULN OR Creatinine clearance least 50 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : At least 4 week since prior levothyroxine Any prior therapy restoration radioiodine uptake allow , unsuccessful exceed treatment schedule plan study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2004</verification_date>
	<keyword>stage IV papillary thyroid cancer</keyword>
	<keyword>stage IV follicular thyroid cancer</keyword>
	<keyword>recurrent thyroid cancer</keyword>
</DOC>